L Kanz
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
Hartmann J, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Investigational new drugs 2006; 24:249-53.
01.05.2006An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
01.05.2006Investigational new drugs 2006; 24:249-53
Hartmann J T, Oechsle K, Huober Jens, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006; 17:1007-13.
13.03.2006A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
13.03.2006Ann Oncol 2006; 17:1007-13
Kollmannsberger C, Schittenhelm Marcus, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C
Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571)
Schittenhelm M, Aichele O, Kröber S, Brümmendorf T, Kanz L, Denzlinger C. Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571). Leuk Lymphoma 2003; 44:1251-3.
01.07.2003Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571)
01.07.2003Leuk Lymphoma 2003; 44:1251-3
Schittenhelm Marcus, Aichele O, Kröber S M, Brümmendorf T, Kanz L, Denzlinger C
Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia
Möhle R, Schittenhelm M, Failenschmid C, Bautz F, Kratz-Albers K, Serve H, Brugger W, Kanz L. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol 2000; 110:563-72.
01.09.2000Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia
01.09.2000Br J Haematol 2000; 110:563-72
Möhle R, Schittenhelm Marcus, Failenschmid C, Bautz F, Kratz-Albers K, Serve H, Brugger W, Kanz L